APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody Drug CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antibody Drug CDMO Service Market Outlook and Growth Opportunities 2026

5 June 2026195 pages

Choose your research edition.

Industry ResearchAntibody Drug CDMO Service Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody Drug CDMO Service Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Antibody Drug CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody Drug CDMO Service Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody Drug CDMO Service Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Antibody Drug CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antibody Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibody Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibody Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antibody Drug CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antibody Drug CDMO Service market include Abzena, AGC Biologics, Axplora, Batavia Biosciences, ChemExpress, FUJIFILM, GTP Bioways, Halix and MYCENAX, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antibody Drug CDMO Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibody Drug CDMO Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibody Drug CDMO Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antibody Drug CDMO Service market.

Antibody Drug CDMO Service Segment by Company

Abzena

AGC Biologics

Axplora

Batavia Biosciences

ChemExpress

FUJIFILM

GTP Bioways

Halix

MYCENAX

WuXi Biologics

ProBio

Samsung Biologics

Sigma-Aldrich

Antibody Drug CDMO Service Segment by Type

Customized Service

Lab-based Service

Others

Antibody Drug CDMO Service Segment by Application

Antibody Drug Conjugates

Monoclonal Antibodies

Others

Antibody Drug CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antibody Drug CDMO Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antibody Drug CDMO Service key companies, revenue, market share, and recent developments.

3. To split the Antibody Drug CDMO Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antibody Drug CDMO Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antibody Drug CDMO Service significant trends, drivers, influence factors in global and regions.

6. To analyze Antibody Drug CDMO Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Drug CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody Drug CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Drug CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antibody Drug CDMO Service industry.

Chapter 3: Detailed analysis of Antibody Drug CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antibody Drug CDMO Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antibody Drug CDMO Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antibody Drug CDMO Service Industry Trends Table 2. Antibody Drug CDMO Service Industry Drivers Table 3. Antibody Drug CDMO Service Industry Opportunities and Challenges Table 4. Antibody Drug CDMO Service Industry Restraints Table 5. Global Antibody Drug CDMO Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antibody Drug CDMO Service Revenue Share by Company (2021-2026) Table 7. Global Antibody Drug CDMO Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antibody Drug CDMO Service Key Company Manufacturing Base & Headquarters Table 9. Global Antibody Drug CDMO Service Company, Product Type & Application Table 10. Global Antibody Drug CDMO Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antibody Drug CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Customized Service Table 15. Significant Companies of Lab-based Service Table 16. Significant Companies of Others Table 17. Global Antibody Drug CDMO Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Antibody Drug CDMO Service Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Antibody Drug CDMO Service Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Antibody Drug CDMO Service Sales Value Share by Type (2021-2026) Table 21. Global Antibody Drug CDMO Service Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Antibody Drug Conjugates Table 23. Significant Companies of Monoclonal Antibodies Table 24. Significant Companies of Others Table 25. Global Antibody Drug CDMO Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antibody Drug CDMO Service Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Antibody Drug CDMO Service Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Antibody Drug CDMO Service Sales Value Share by Application (2021-2026) Table 29. Global Antibody Drug CDMO Service Sales Value Share by Application (2027-2032) Table 30. Global Antibody Drug CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Antibody Drug CDMO Service Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Antibody Drug CDMO Service Sales Value Share by Region (2021-2026) Table 33. Global Antibody Drug CDMO Service Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Antibody Drug CDMO Service Sales Value Share by Region (2027-2032) Table 35. Global Antibody Drug CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antibody Drug CDMO Service Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Antibody Drug CDMO Service Sales Value Market Share by Country (2021-2026) Table 38. Global Antibody Drug CDMO Service Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Antibody Drug CDMO Service Sales Value Market Share by Country (2027-2032) Table 40. Abzena Company Information Table 41. Abzena Business Overview Table 42. Abzena Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Abzena Antibody Drug CDMO Service Product Portfolio Table 44. Abzena Recent Development Table 45. AGC Biologics Company Information Table 46. AGC Biologics Business Overview Table 47. AGC Biologics Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. AGC Biologics Antibody Drug CDMO Service Product Portfolio Table 49. AGC Biologics Recent Development Table 50. Axplora Company Information Table 51. Axplora Business Overview Table 52. Axplora Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Axplora Antibody Drug CDMO Service Product Portfolio Table 54. Axplora Recent Development Table 55. Batavia Biosciences Company Information Table 56. Batavia Biosciences Business Overview Table 57. Batavia Biosciences Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Batavia Biosciences Antibody Drug CDMO Service Product Portfolio Table 59. Batavia Biosciences Recent Development Table 60. ChemExpress Company Information Table 61. ChemExpress Business Overview Table 62. ChemExpress Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. ChemExpress Antibody Drug CDMO Service Product Portfolio Table 64. ChemExpress Recent Development Table 65. FUJIFILM Company Information Table 66. FUJIFILM Business Overview Table 67. FUJIFILM Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. FUJIFILM Antibody Drug CDMO Service Product Portfolio Table 69. FUJIFILM Recent Development Table 70. GTP Bioways Company Information Table 71. GTP Bioways Business Overview Table 72. GTP Bioways Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. GTP Bioways Antibody Drug CDMO Service Product Portfolio Table 74. GTP Bioways Recent Development Table 75. Halix Company Information Table 76. Halix Business Overview Table 77. Halix Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Halix Antibody Drug CDMO Service Product Portfolio Table 79. Halix Recent Development Table 80. MYCENAX Company Information Table 81. MYCENAX Business Overview Table 82. MYCENAX Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. MYCENAX Antibody Drug CDMO Service Product Portfolio Table 84. MYCENAX Recent Development Table 85. WuXi Biologics Company Information Table 86. WuXi Biologics Business Overview Table 87. WuXi Biologics Antibody Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. WuXi Biologics Antibody Drug CDMO Service Product Portfolio Table 89. WuXi Biologics Recent Development Table 90. ProBio Company Information Table 91. ProBio Business Overview Table 92. ProBio Antibody Drug CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. ProBio Antibody Drug CDMO Service Product Portfolio Table 94. ProBio Recent Development Table 95. Samsung Biologics Company Information Table 96. Samsung Biologics Business Overview Table 97. Samsung Biologics Antibody Drug CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Samsung Biologics Antibody Drug CDMO Service Product Portfolio Table 99. Samsung Biologics Recent Development Table 100. Sigma-Aldrich Company Information Table 101. Sigma-Aldrich Business Overview Table 102. Sigma-Aldrich Antibody Drug CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Sigma-Aldrich Antibody Drug CDMO Service Product Portfolio Table 104. Sigma-Aldrich Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Antibody Drug CDMO Service Product Image Figure 2. Global Antibody Drug CDMO Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody Drug CDMO Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Antibody Drug CDMO Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Customized Service Image Figure 8. Lab-based Service Image Figure 9. Others Image Figure 10. Global Antibody Drug CDMO Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Antibody Drug CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Antibody Drug CDMO Service Sales Value Share by Type (2021-2032) Figure 13. Antibody Drug Conjugates Image Figure 14. Monoclonal Antibodies Image Figure 15. Others Image Figure 16. Global Antibody Drug CDMO Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antibody Drug CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Antibody Drug CDMO Service Sales Value Share by Application (2021-2032) Figure 19. Global Antibody Drug CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Antibody Drug CDMO Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Antibody Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 22. North America Antibody Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Antibody Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Antibody Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Antibody Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Antibody Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Antibody Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 28. South America Antibody Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Antibody Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Antibody Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Customized Service
  • Lab-based Service
  • Others
Applications
  • Antibody Drug Conjugates
  • Monoclonal Antibodies
  • Others
Companies covered
  • Abzena
  • AGC Biologics
  • Axplora
  • Batavia Biosciences
  • ChemExpress
  • FUJIFILM
  • GTP Bioways
  • Halix
  • MYCENAX
  • WuXi Biologics
  • ProBio
  • Samsung Biologics
  • Sigma-Aldrich

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antibody Drug CDMO Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antibody Drug CDMO Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antibody Drug CDMO Service Market Dynamics
  1. 2.1 Antibody Drug CDMO Service Industry Trends
  2. 2.2 Antibody Drug CDMO Service Industry Drivers
  3. 2.3 Antibody Drug CDMO Service Industry Opportunities and Challenges
  4. 2.4 Antibody Drug CDMO Service Industry Restraints
3 Antibody Drug CDMO Service Market by Company
  1. 3.1 Global Antibody Drug CDMO Service Company Revenue Ranking in 2025
  2. 3.2 Global Antibody Drug CDMO Service Revenue by Company (2021-2026)
  3. 3.3 Global Antibody Drug CDMO Service Company Ranking (2024-2026)
  4. 3.4 Global Antibody Drug CDMO Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Antibody Drug CDMO Service Company Product Type and Application
  6. 3.6 Global Antibody Drug CDMO Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antibody Drug CDMO Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antibody Drug CDMO Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antibody Drug CDMO Service Market by Type
  1. 4.1 Antibody Drug CDMO Service Type Introduction
  2. 4.1.1 Customized Service
  3. 4.1.2 Lab-based Service
  4. 4.1.3 Others
  5. 4.2 Global Antibody Drug CDMO Service Sales Value by Type
  6. 4.2.1 Global Antibody Drug CDMO Service Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antibody Drug CDMO Service Sales Value by Type (2021-2032)
  8. 4.2.3 Global Antibody Drug CDMO Service Sales Value Share by Type (2021-2032)
5 Antibody Drug CDMO Service Market by Application
  1. 5.1 Antibody Drug CDMO Service Application Introduction
  2. 5.1.1 Antibody Drug Conjugates
  3. 5.1.2 Monoclonal Antibodies
  4. 5.1.3 Others
  5. 5.2 Global Antibody Drug CDMO Service Sales Value by Application
  6. 5.2.1 Global Antibody Drug CDMO Service Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antibody Drug CDMO Service Sales Value by Application (2021-2032)
  8. 5.2.3 Global Antibody Drug CDMO Service Sales Value Share by Application (2021-2032)
6 Antibody Drug CDMO Service Regional Value Analysis
  1. 6.1 Global Antibody Drug CDMO Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibody Drug CDMO Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antibody Drug CDMO Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antibody Drug CDMO Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antibody Drug CDMO Service Sales Value (2021-2032)
  7. 6.3.2 North America Antibody Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antibody Drug CDMO Service Sales Value (2021-2032)
  10. 6.4.2 Europe Antibody Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antibody Drug CDMO Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antibody Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antibody Drug CDMO Service Sales Value (2021-2032)
  16. 6.6.2 South America Antibody Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antibody Drug CDMO Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antibody Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
7 Antibody Drug CDMO Service Country-level Value Analysis
  1. 7.1 Global Antibody Drug CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antibody Drug CDMO Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antibody Drug CDMO Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antibody Drug CDMO Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antibody Drug CDMO Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antibody Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antibody Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abzena
  2. 8.1.1 Abzena Company Information
  3. 8.1.2 Abzena Business Overview
  4. 8.1.3 Abzena Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abzena Antibody Drug CDMO Service Product Portfolio
  6. 8.1.5 Abzena Recent Developments
  7. 8.2 AGC Biologics
  8. 8.2.1 AGC Biologics Company Information
  9. 8.2.2 AGC Biologics Business Overview
  10. 8.2.3 AGC Biologics Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AGC Biologics Antibody Drug CDMO Service Product Portfolio
  12. 8.2.5 AGC Biologics Recent Developments
  13. 8.3 Axplora
  14. 8.3.1 Axplora Company Information
  15. 8.3.2 Axplora Business Overview
  16. 8.3.3 Axplora Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Axplora Antibody Drug CDMO Service Product Portfolio
  18. 8.3.5 Axplora Recent Developments
  19. 8.4 Batavia Biosciences
  20. 8.4.1 Batavia Biosciences Company Information
  21. 8.4.2 Batavia Biosciences Business Overview
  22. 8.4.3 Batavia Biosciences Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Batavia Biosciences Antibody Drug CDMO Service Product Portfolio
  24. 8.4.5 Batavia Biosciences Recent Developments
  25. 8.5 ChemExpress
  26. 8.5.1 ChemExpress Company Information
  27. 8.5.2 ChemExpress Business Overview
  28. 8.5.3 ChemExpress Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ChemExpress Antibody Drug CDMO Service Product Portfolio
  30. 8.5.5 ChemExpress Recent Developments
  31. 8.6 FUJIFILM
  32. 8.6.1 FUJIFILM Company Information
  33. 8.6.2 FUJIFILM Business Overview
  34. 8.6.3 FUJIFILM Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 FUJIFILM Antibody Drug CDMO Service Product Portfolio
  36. 8.6.5 FUJIFILM Recent Developments
  37. 8.7 GTP Bioways
  38. 8.7.1 GTP Bioways Company Information
  39. 8.7.2 GTP Bioways Business Overview
  40. 8.7.3 GTP Bioways Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GTP Bioways Antibody Drug CDMO Service Product Portfolio
  42. 8.7.5 GTP Bioways Recent Developments
  43. 8.8 Halix
  44. 8.8.1 Halix Company Information
  45. 8.8.2 Halix Business Overview
  46. 8.8.3 Halix Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Halix Antibody Drug CDMO Service Product Portfolio
  48. 8.8.5 Halix Recent Developments
  49. 8.9 MYCENAX
  50. 8.9.1 MYCENAX Company Information
  51. 8.9.2 MYCENAX Business Overview
  52. 8.9.3 MYCENAX Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 MYCENAX Antibody Drug CDMO Service Product Portfolio
  54. 8.9.5 MYCENAX Recent Developments
  55. 8.10 WuXi Biologics
  56. 8.10.1 WuXi Biologics Company Information
  57. 8.10.2 WuXi Biologics Business Overview
  58. 8.10.3 WuXi Biologics Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 WuXi Biologics Antibody Drug CDMO Service Product Portfolio
  60. 8.10.5 WuXi Biologics Recent Developments
  61. 8.11 ProBio
  62. 8.11.1 ProBio Company Information
  63. 8.11.2 ProBio Business Overview
  64. 8.11.3 ProBio Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 ProBio Antibody Drug CDMO Service Product Portfolio
  66. 8.11.5 ProBio Recent Developments
  67. 8.12 Samsung Biologics
  68. 8.12.1 Samsung Biologics Company Information
  69. 8.12.2 Samsung Biologics Business Overview
  70. 8.12.3 Samsung Biologics Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Samsung Biologics Antibody Drug CDMO Service Product Portfolio
  72. 8.12.5 Samsung Biologics Recent Developments
  73. 8.13 Sigma-Aldrich
  74. 8.13.1 Sigma-Aldrich Company Information
  75. 8.13.2 Sigma-Aldrich Business Overview
  76. 8.13.3 Sigma-Aldrich Antibody Drug CDMO Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sigma-Aldrich Antibody Drug CDMO Service Product Portfolio
  78. 8.13.5 Sigma-Aldrich Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst